Barcelona

• Randomized Clinical Trial on Oxytocin and Self-Compassion Training in Borderline Personality Disorder Recruiting
  2024-515589-15-00 6 2024-07-25 Borderline Personality Disorder.
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer Recruiting
  2023-504330-21-00 1 2024-07-22 advanced/metastatic solid tumors
• A study to investigate efficacy, safety, and tolerability of mavorixafor in participants with congenital and acquired primary autoimmune and … Recruiting
  2023-508482-32-00 5 2024-07-22 Neutropenias
• Study of RMC-6291 and RMC-6236 With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A Recruiting
  2023-509571-16-00 3 2024-07-17 Lung Cancer
• A study of RMC-6236 in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B Recruiting
  2023-509572-42-00 3 2024-07-17 Lung Cancer
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting
  2023-508162-15-00 5 2024-07-12 Chronic HF and comorbid impairment of kidney function who had a recent
• A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting
  2022-502629-16-00 5 2024-07-10 Hemolytic Disease of the Fetus and Newborn (HDFN)
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting
  2023-508178-27-00 9 2024-07-10 Participants with Advanced KRASG12C-Mutated Solid Tumors
• Beta-Blockers in Takotsubo Syndrome: A Randomized Clinical Trial Recruiting
  2023-510213-25-01 6 2024-07-08 Takotsubo Syndrome (TT) is an acute cardiac condition
• Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer Recruiting
  2023-510536-37-00 4 2024-07-05 Prostate Cancer
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• LONGITUDINAL STUDY OF THE POSITRON EMISSION TOMOGRAPHY (PET) TRACER FOR TAU 18F-PI-2620 IN INDIVIDUALS WITH DOWN SYNDROME Recruiting
  2024-515574-27-00 4 2024-07-03 Down Syndrome
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i … Recruiting
  2023-508204-38-00 5 2024-07-02 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 Oligometastatic prostate cancer (OMPC)
• Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study) Recruiting
  2023-510508-31-01 4 2024-07-01 cognitive impairment
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• A Study Evaluating the Efficacy and Safety of Povorcitinib (INCB054707) in Adults With Inadequately Controlled Moderate to Severe Asthma Recruiting
  2022-502570-16-01 4 2024-06-27 Treatment of patients with inadequately controlled moderate to severe
• Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induc … Recruiting
  2024-514880-25-00 5 2024-06-27 Patients with cardiovascular alterations induced by cirrhosis, diabete
• An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with ad … Recruiting
  2023-504199-19-00 7 2024-06-26 Solid Tumours
• Efficacy of perioperative duloxetine in patients at high risk for developing chronic postsurgical pain after inguinal hernia repair: a multi … Recruiting
  2023-505860-12-00 5 2024-06-26 Chronic postsurgical pain after inguinal hernia repair

Showing 1,273–1,296 of 3,391 trials